The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults. Jascayd becomes the first and only preferential ...

The U.S. Food and Drug Administration (FDA) has approved Jascayd (nerandomilast), taken as oral tablets, as a treatment for adults with progressive pulmonary fibrosis (PPF), in which lung scarring ...

AI-based imaging tools have shown potential in detecting treatment responses in IPF, supporting the use of ENV-101 and AI imaging as trial endpoints. The forced oscillation technique (FOT) may enhance ...

Pemvidutide, an investigational drug that is a dual agonist for GLP-1 and glucagon receptors, significantly improved fibrosis in adults with metabolic dysfunction-associated steatohepatitis (MASH) and ...

Obesity is a well-established risk factor for erectile dysfunction (ED); however, the long-term vascular consequences of early-life obesity on corpus cavernosum (CC) and pudendal artery (PA) function ...

Resolution of steatohepatitis with no worsening of liver fibrosis was achieved in 63% of patients taking semaglutide vs 34% taking placebo at week 72. The Food and Drug Administration (FDA) has ...

Aug 4 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab beat Wall Street estimates for quarterly results on Monday, helped by demand for its new cystic fibrosis drug and product launches.

Recently these monocyte-derived alveolar macrophages, or Mo-AMs, were identified as key drivers of lung fibrosis disease progression. However, the mechanisms of their pro-fibrotic behavior and ...

As an undergraduate student in the early 1980s, Marie Egan volunteered at the Children’s Hospital of Philadelphia. She’d often spend time in the hospital playrooms with children with serious illnesses ...

Cystic fibrosis (CF) is a genetic disorder that causes thick, sticky mucus to build up in the lungs, digestive system and other organs Morgan Barrett; Brittyn Elizabeth Studios From a very young age, ...